知镜 Cognispect · 医学文献与研究工作台

Urinary podocalyxin as an early biomarker for diabetic nephropathy.

Hossain MS, Dwipi ST, Ahmed N, Murshed KM, Aftab KA, Al Mahdi A, Hoque MM, Taraq MJH, Hussain MZ, Azad MAK.
PloS one · 2026-07-23 · PMID 42490553

文献摘要

Background Conventional biomarkers, such as the urinary albumin-to-creatinine ratio (uACR), detect diabetic nephropathy (DN) late in its course and may miss early podocyte injury. Urinary podocalyxin (u-PDX), a sialylated glycoprotein shed from podocytes, may offer an earlier means of detection. Methods We conducted a cross-sectional analytical study at Bangabandhu Sheikh Mujib Medical University between March 2023 and August 2024. Eighty-eight adults were enrolled: 59 participants with type 2 diabetes mellitus (T2DM) and 29 healthy controls. Participants with diabetes were stratified into normoalbuminuric (n = 29), microalbuminuric (n = 15), and macroalbuminuric (n = 15) subgroups based on uACR. Clinical variables and biochemical indices were recorded. u-PDX concentrations were measured using ELISA, and associations with uACR and eGFR were analyzed using Kendall's tau-b and Pearson's correlation coefficients. Diagnostic performance was assessed using receiver operating characteristic (ROC) curves with bootstrap internal validation. Results Among participants with diabetes, u-PDX levels increased progressively across normo-, micro-, and macroalbuminuric groups (p Conclusions Urinary podocalyxin is a sensitive early biomarker of diabetic nephropathy, rising before overt albuminuria and correlating with albuminuria severity and declining eGFR. However, longitudinal validation is required before u-PDX can be recommended for routine screening in adults with T2DM.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。